% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Jul 1, 2013 8:37 PM Flag

    lazard says this

    1:07 PM Lazard says Arikace is "still viable," which will hopefully be some consolation for Insmed (INSM -15.4%) shareholders who are taking a rather nasty hit right now courtesy of Phase 3 trial results (previous) which suggested CF patients treated with Novartis' (NVS +0.4%) Tobi performed better on lung function tests — the results were close enough however, to allow INSM to claim statistical non-inferiority. Lazard's Joshua Schimmer reiterates a Buy rating and a $24 price target. Investors are also reminded that UBS believes the drug's real potential might lie in non-tuberculous mycobacteria rather than CF. Read comments

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Insmed sell-off on Arikace data overdone, says Canaccord: Canaccord views the sell-off in shares of Insmed as overdone and keeps a Buy rating on the stock. The firm says Arikace’s activity in Cystic Fibrosis is supportive of good drug localization to deep lung and upped its price target for shares to $18 from $17

12.77-0.04(-0.31%)3:59 PMEST